At a glance
- Note: These files are not yet 508
- Slides will be added as they become available.
February 22, 2023
Welcome & Introductions
Introduction
Dr. G Lee
Dr. M Wharton
Mpox Vaccine
Dr. Pablo Sanchez
Epidemiology of mpox during 2022 outbreak in the United States [18 pages]
Dr. Sascha Ellington
JYNNEOS Vaccine Safety [26 pages]
Dr. Jonathan Duffy
JYNNEOS Vaccine Effectiveness [21 pages]
Dr. Anna Chard
Mpox vaccine acceptability and uptake from cross-sectional surveys [26 pages]
Dr. Kevin P. Delaney
Interim Clinical Considerations [12 pages]
Dr. Rosalind Carter
EtR: Use of JYNNEOS during mpox outbreaks [48 pages]
Dr. Agam Rao
Respiratory disease surge, Fall 2022, United States
Dr. José R. Romero
Influenza Vaccine
Dr. Keipp Talbot
U.S. Influenza activity update [7 pages]
Dr. Lisa Grohskopf
Preliminary 2022-23 influenza vaccine effectiveness: CDC networks [25 pages]
Ms. Samantha Olson, Dr. Nathaniel Lewis, Dr. Mark Tenforde
Preliminary 2022-23 influenza vaccine effectiveness: Wisconsin [15 pages]
Dr. Huong McClean
Published Estimates of LAIV Effectiveness [4 pages]
Dr. Lisa Grohskopf
Pneumococcal Vaccines
Dr. Katherine Poehling
Epidemiology of pneumococcal disease among U.S. children [21 pages]
Mr. Ryan Gierke
Ms. Laura King
PCV20 Phase 2/3 study results among children [18 pages]
Dr. Wendy Watson
Preliminary EtR (incl. GRADE) for PCV20 use in U.S. children [57 pages]
Dr. Miwako Kobayashi
Workgroup considerations [12 pages]
Dr. Miwako Kobayashi
February 23, 2023
Welcome & Introductions
Introduction
Dr. G Lee
Dr. M Wharton
Agency Updates
Meningococcal Vaccines
Dr. Kathy Poehling
Epidemiology of meningococcal disease in the United States [17 pages]
Ms. Amy Rubis
Pfizer pentavalent meningococcal vaccine [26 pages]
Dr. Jason Maguire
Workgroup considerations [15 pages]
Dr. Sam Crowe
Polio Vaccine
Dr. Oliver Brooks
Recommendations for Adult Polio Vaccination [29 pages]
Dr. Sarah Kidd
RSV Vaccines – Pediatric/Maternal
Dr. S Long
Cost effectiveness analysis for nirsevimab – CDC model [40 pages]
Dr. David Hutton
Cost effectiveness analysis for nirsevimab – Comparison to manufacturer model [23 pages]
Dr. Ismael Ortega Sanchez
Evidence to Recommendations framework for nirsevimab [92 pages]
Dr. Jefferson Jones
Clinical considerations for nirsevimab [16 pages]
Dr. Jefferson Jones
Safety and Efficacy of RSV Bivalent PreF Maternal Vaccine [31 pages]
Dr. Iona Munjal
Workgroup considerations [6 pages]
Dr. Katherine Fleming-Dutra
RSV Vaccines – Adult
Dr. Camille Kotton
Cost effectiveness of the GSK and Pfizer vaccines (main CDC model) [37 pages]
Dr. David Hutton
Dr. Ismael Ortega Sanchez
EtR (incl. GRADE) for 2 vaccines (GSK & Pfizer) [90 pages]
Dr. Michael Melgar
Vaccine policy questions (GSK & Pfizer) [2 pages]
Dr. Michael Melgar
Chikungunya Vaccine
Dr. Beth Bell
Global epidemiology of chikungunya [12 pages]
Dr. Susan Hills
Chikungunya in U.S. travelers [15 pages]
Ms. Nicole Lindsey
Persistent arthralgia following chikungunya [21 pages]
Ms. Nicole Lindsey
Workgroup considerations [4 pages]
Ms. Nicole Lindsey
Dengue Vaccines
Dr. W Chen
Takeda dengue vaccine (TAK-003) safety and efficacy [26 pages]
Dr. Shibidas Biswal
Workgroup considerations [22 pages]
Dr. Gabriela Paz-Bailey
Varicella
Public health impact of 25 years of varicella vaccination in the United States [23 pages]
Dr. Mona Marin
February 24, 2023
Welcome & Introductions
Introduction
Dr. G Lee
Dr. M Wharton
COVID-19 Vaccines
Dr. Matthew Daley
COVID-19 vaccine safety updates: CDC [43 pages]
Dr. Tom Shimabukuro
COVID-19 vaccine safety updates: FDA [17 pages]
Dr. Richard Forshee
Dr. Keipp Talbot
WG interpretation and summary [19 pages]
Dr. Evelyn Twentyman
Updates on COVID-19 hospitalizations: COVID-NET [14 pages]
Dr. Chris Taylor
Updates to COVID-19 vaccine effectiveness in the United States [29 pages]
Dr. Amadea Britton
Considerations for transitioning to bivalent primary series [32 pages]
Dr. Sara Oliver
Benefit/risk for COVID-19 vaccines [21 pages]
Dr. Megan Wallace
COVID-19 vaccines: future directions [37 pages]
Dr. Sara Oliver